Table 3.
Absolute incidence rates (IRs) and pairwise comparison of each biologic* to every other for subsequent hospitalized infection. Data shown are adjusted hazard ratios‡ with 95% confidence interval (CI).
| Biologies | Referent Group | ||||
|---|---|---|---|---|---|
| Infliximab | Adalimumab | Etanercept | Rituximab | Abatacept | |
| Crude IR Per 100 years (n/pys†) | 33.8 (1,382/4,087) | 34.9 (497/1,423) | 36.1 (661/1,831) | 28.5 (38/133) | 26.5 (88/333) |
| Adjusted HR (95% CI) ‡ | |||||
| Abatacept | 0.80 (0.64-0.99) | 0.88 (0.68-1.12) | 0.97 (0.76-1.23) | 0.93 (0.64-1.36) | 1.0 (Ref) |
| Rituximab | 0.87 (0.63-1.20) | 0.94 (0.67-1.32) | 1.04 (0.74-1.46) | 1.0 (Ref) | |
| Etanercept | 0.83 (0.72-0.97) | 0.91 (0.76-1.08) | 1.0 (Ref) | ||
| Adalimumab | 0.92 (0.79-1.09) | 1.0 (Ref) | |||
| Infliximab | 1.0 (Ref) | ||||
*
Biologic exposure was defined as the days' supply from filled prescriptions or assigned days' supply based on recommended dosing frequency, plus a 30-day 'extension' period to each exposure.
†
Person years
‡
Adjusted for the decile of disease risk score, specific anti-TNF biologic at the time of the index hospitalization, steroid use during baseline, methotrexate use during baseline, infection type for the index hospitalization, and coexisting medication exposures during follow up.